<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1453" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1453/" /><meta name="ncbi_pagename" content="X-Linked Agammaglobulinemia - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>X-Linked Agammaglobulinemia - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="X-Linked Agammaglobulinemia" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2016/08/04" /><meta name="citation_author" content="CI Edvard Smith" /><meta name="citation_author" content="Anna Berglöf" /><meta name="citation_pmid" content="20301626" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1453/" /><meta name="citation_keywords" content="Bruton's Agammaglobulinemia" /><meta name="citation_keywords" content="XLA" /><meta name="citation_keywords" content="Bruton's Agammaglobulinemia" /><meta name="citation_keywords" content="XLA" /><meta name="citation_keywords" content="Tyrosine-protein kinase BTK" /><meta name="citation_keywords" content="BTK" /><meta name="citation_keywords" content="X-Linked Agammaglobulinemia" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="X-Linked Agammaglobulinemia" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="CI Edvard Smith" /><meta name="DC.Contributor" content="Anna Berglöf" /><meta name="DC.Date" content="2016/08/04" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1453/" /><meta name="description" content="X-linked agammaglobulinemia (XLA) is characterized by recurrent bacterial infections in affected males in the first two years of life. Recurrent otitis is the most common infection prior to diagnosis. Conjunctivitis, sinopulmonary infections, diarrhea, and skin infections are also frequently seen. Approximately 60% of individuals with XLA are recognized as having immunodeficiency when they develop a severe, life-threatening infection such as pneumonia, empyema, meningitis, sepsis, cellulitis, or septic arthritis. S pneumoniae and H influenzae are the most common organisms found prior to diagnosis and may continue to cause sinusitis and otitis after diagnosis and the initiation of gammaglobulin substitution therapy. Severe, difficult-to-treat enteroviral infections (often manifest as dermatomyositis or chronic meningoencephalitis) can be prevented by this treatment. The prognosis for individuals with XLA has improved markedly in the last 25 years as a result of earlier diagnosis, the development of preparations of gammaglobulin that allow normal concentrations of serum IgG to be achieved, and more liberal use of antibiotics." /><meta name="og:title" content="X-Linked Agammaglobulinemia" /><meta name="og:type" content="book" /><meta name="og:description" content="X-linked agammaglobulinemia (XLA) is characterized by recurrent bacterial infections in affected males in the first two years of life. Recurrent otitis is the most common infection prior to diagnosis. Conjunctivitis, sinopulmonary infections, diarrhea, and skin infections are also frequently seen. Approximately 60% of individuals with XLA are recognized as having immunodeficiency when they develop a severe, life-threatening infection such as pneumonia, empyema, meningitis, sepsis, cellulitis, or septic arthritis. S pneumoniae and H influenzae are the most common organisms found prior to diagnosis and may continue to cause sinusitis and otitis after diagnosis and the initiation of gammaglobulin substitution therapy. Severe, difficult-to-treat enteroviral infections (often manifest as dermatomyositis or chronic meningoencephalitis) can be prevented by this treatment. The prognosis for individuals with XLA has improved markedly in the last 25 years as a result of earlier diagnosis, the development of preparations of gammaglobulin that allow normal concentrations of serum IgG to be achieved, and more liberal use of antibiotics." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1453/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/xla/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1453/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8808FDE04015210000000006D70270.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1453_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1453_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/x-ald/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/csnb/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1453_"><span class="title" itemprop="name">X-Linked Agammaglobulinemia</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonyms: Bruton's Agammaglobulinemia, XLA</div><p class="contrib-group"><span itemprop="author">CI Edvard Smith</span>, MD, PhD and <span itemprop="author">Anna Bergl&#x000f6;f</span>, VMD, PhD.</p><a data-jig="ncbitoggler" href="#__NBK1453_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1453_ai__"><div class="contrib half_rhythm"><span itemprop="author">CI Edvard Smith</span>, MD, PhD<div class="affiliation small">Karolinska Institutet<br />Stockholm, Sweden<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="es.ik@htims.dravde" class="oemail">es.ik@htims.dravde</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Anna Bergl&#x000f6;f</span>, VMD, PhD<div class="affiliation small">Karolinska Institutet<br />Stockholm, Sweden<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="es.ik@folgreb.anna" class="oemail">es.ik@folgreb.anna</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">April 5, 2001</span>; Last Update: <span itemprop="dateModified">August 4, 2016</span>.</p><p><em>Estimated reading time: 19 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="xla.Summary" itemprop="description"><h2 id="_xla_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p><a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> agammaglobulinemia (XLA) is characterized by recurrent bacterial infections in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males in the first two years of life. Recurrent otitis is the most common infection prior to diagnosis. Conjunctivitis, sinopulmonary infections, diarrhea, and skin infections are also frequently seen. Approximately 60% of individuals with XLA are recognized as having immunodeficiency when they develop a severe, life-threatening infection such as pneumonia, empyema, meningitis, sepsis, cellulitis, or septic arthritis. <i>S pneumoniae</i> and <i>H influenzae</i> are the most common organisms found prior to diagnosis and may continue to cause sinusitis and otitis after diagnosis and the initiation of gammaglobulin substitution therapy. Severe, difficult-to-treat enteroviral infections (often manifest as dermatomyositis or chronic meningoencephalitis) can be prevented by this treatment. The prognosis for individuals with XLA has improved markedly in the last 25 years as a result of earlier diagnosis, the development of preparations of gammaglobulin that allow normal concentrations of serum IgG to be achieved, and more liberal use of antibiotics.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of XLA is suspected in males with early-onset bacterial infections, marked reduction in all classes of serum immunoglobulins, and absent B cells (CD19+ cells); the decrease in the number of B cells is the most consistent and distinctive feature. Adenoids and tonsils are frequently rudimentary and lymph nodes are reduced in size. Having a maternal uncle or male cousin with absent B cells makes the diagnosis almost certain. The diagnosis is established (or confirmed) in males who have a <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> <i>BTK</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> and females who have a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>BTK</i> pathogenic variant.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> The mainstay of treatment is gammaglobulin substitution therapy (by weekly subcutaneous injection or intravenous infusion every 2-4 weeks) to prevent bacterial infections; some centers use chronic prophylactic antibiotics to prevent infections.</p><p><i>Prevention of secondary complications:</i> The most common secondary complications of XLA are chronic sinusitis, chronic lung disease, inflammatory bowel disease, and enteroviral infection. Generous use of antibiotics can decrease the incidence of chronic sinusitis and lung disease. Diagnosis and treatment of bowel infections may decrease the risk of inflammatory bowel disease.</p><p><i>Agents/circumstances to avoid:</i> Live viral vaccines, particularly oral polio vaccine; inactivated polio vaccine rather than live oral polio vaccine should be given to patients and their family contacts.</p><p><i>Evaluation of relatives at risk:</i> Molecular genetic testing of at-risk male relatives as soon after birth as possible ensures that gammaglobulin substitution therapy is initiated as soon as possible in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>XLA is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> manner. The risk to the sibs depends on the <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status of the mother: if the mother is <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a <i>BTK</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, there is a 50% chance of transmitting the <i>BTK</i> pathogenic variant in each pregnancy; males who inherit the pathogenic variant will be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>; females who inherit the pathogenic variant will be carriers. All daughters of a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> will inherit the <i>BTK</i> pathogenic variant and will be carriers; sons are not affected. Once the <i>BTK</i> pathogenic variant has been identified in an affected family member, <a class="def" href="/books/n/gene/glossary/def-item/carrier-testing/">carrier testing</a> for at-risk females is possible and prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible options.</p></div></div><div id="xla.Diagnosis"><h2 id="_xla_Diagnosis_">Diagnosis</h2><div id="xla.Suggestive_Findings"><h3>Suggestive Findings</h3><p><a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> agammaglobulinemia (XLA) <b>should be suspected</b> in an individual with the following clinical history, laboratory findings, and family history.</p><p><b>Clinical history.</b> Any of the following:</p><ul><li class="half_rhythm"><div>Recurrent otitis, pneumonitis, sinusitis, and conjunctivitis starting before age five years</div></li><li class="half_rhythm"><div>A severe life-threatening bacterial infection such as sepsis, meningitis, cellulitis, or empyema</div></li><li class="half_rhythm"><div>Paucity of lymphoid tissue (small adenoids, tonsils, and lymph nodes on physical examination)</div></li></ul><p><b>Laboratory findings</b></p><ul><li class="half_rhythm"><div><b>Marked reduction in all classes of serum immunoglobulins</b> [<a class="bk_pop" href="#xla.REF.lederman.1985.145">Lederman &#x00026; Winkelstein 1985</a>, <a class="bk_pop" href="#xla.REF.conley.2005.216">Conley et al 2005</a>]</div><ul><li class="half_rhythm"><div>The serum IgG concentration is typically &#x0003c;200 mg/dL (2 g/L). Most but not all individuals with XLA do have some measurable serum IgG, usually between 100 and 200 mg/dL, and ~10% of individuals have serum concentration of IgG &#x0003e;200 mg/dL.</div></li><li class="half_rhythm"><div>The serum concentrations of IgM and IgA are typically &#x0003c;20 mg/dL. Particular attention should be given to serum IgM concentration. Although decreased serum concentration of IgG and IgA can be seen in children with a constitutional delay in immunoglobulin production, low serum IgM concentration is almost always associated with immunodeficiency.</div></li></ul></li><li class="half_rhythm"><div><b>Markedly reduced numbers of B lymphocytes</b> (CD 19+ cells) in the peripheral circulation (&#x0003c;1%) [<a class="bk_pop" href="#xla.REF.conley.1985.3070">Conley 1985</a>, <a class="bk_pop" href="#xla.REF.nonoyama.1998.3925">Nonoyama et al 1998</a>]</div></li><li class="half_rhythm"><div><b>Antibody titers to vaccine antigens.</b> Individuals with XLA fail to make antibodies to vaccine antigens like tetanus, <i>H influenzae</i>, or <i>S pneumoniae.</i></div></li><li class="half_rhythm"><div><b>Severe neutropenia</b> in ~10%-25% of individuals at the time of diagnosis, usually in association with pseudomonas or staphylococcal sepsis [<a class="bk_pop" href="#xla.REF.conley.2002.566">Conley &#x00026; Howard 2002</a>]</div></li></ul><p><b>Family history</b> of immunodeficiency consistent with <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> inheritance</p></div><div id="xla.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p><b>Male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The diagnosis of XLA <b>is established</b> in a male proband with suggestive clinical and laboratory findings and identification of a <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>BTK</i> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1453/table/xla.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figxlaTmoleculargenetictestingusedin" rid-ob="figobxlaTmoleculargenetictestingusedin">Table 1</a>).</p><p>Molecular genetic testing approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b>, use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>, and <b>more comprehensive</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>BTK</i> is performed first followed by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> if no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found.</div><div class="half_rhythm">Note: (1) Because approximately 3%-5% of individuals with a <i>BTK</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> have large deletions that include all or part of <i>BTK</i> and the closely linked <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <i>TIMM8A</i> (also called <i>DDP</i>) resulting in XLA and <a href="/books/n/gene/ddon/">deafness-dystonia-optic neuropathy syndrome</a> (DDON; also called Mohr-Tranebj&#x000e6;rg syndrome) [<a class="bk_pop" href="#xla.REF.richter.2001.107">Richter et al 2001</a>, <a class="bk_pop" href="#xla.REF.sediv_.2007.640">Sediv&#x000e1; et al 2007</a>], additional testing with <a class="def" href="/books/n/gene/glossary/def-item/chromosomal-microarray/">chromosomal microarray</a> analysis (CMA) may be warranted. (2) For individuals with clinical features of XLA and DDON, consider CMA testing first.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>BTK</i> and other genes of interest (see <a href="#xla.Differential_Diagnosis">Differential Diagnosis</a>) may also be considered. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>More comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (when available) including <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a> and <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a> may be considered if serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing (and/or use of a <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a> that includes <i>BTK</i>) fails to confirm a diagnosis in an individual with features of XLA. Such testing may also provide or suggest a diagnosis not previously considered (e.g., mutation of a different gene or genes that results in a similar clinical presentation). For an introduction to comprehensive genomic testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</div></li></ul><div id="xla.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in X-Linked Agammaglobulinemia (XLA)</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1453/table/xla.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__xla.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_xla.T.molecular_genetic_testing_used_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_xla.T.molecular_genetic_testing_used_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_xla.T.molecular_genetic_testing_used_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by Method</th></tr></thead><tbody><tr><td headers="hd_h_xla.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>BTK</i></td><td headers="hd_h_xla.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3,&#x000a0;4,&#x000a0;5</sup></td><td headers="hd_h_xla.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">92%</td></tr><tr><td headers="hd_h_xla.T.molecular_genetic_testing_used_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>6</sup></td><td headers="hd_h_xla.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">8%</td></tr><tr><td headers="hd_h_xla.T.molecular_genetic_testing_used_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">CMA&#x000a0;<sup>7</sup></td><td headers="hd_h_xla.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3%-5%&#x000a0;<sup>8</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="xla.TF.1.1"><p class="no_margin">See <a href="/books/NBK1453/#xla.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="xla.TF.1.2"><p class="no_margin">See <a href="#xla.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="xla.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="xla.TF.1.4"><p class="no_margin">Lack of amplification by <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a> prior to <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> can suggest a putative (multi)<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> on the X <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males; confirmation requires additional testing by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>.</p></div></dd><dt>5. </dt><dd><div id="xla.TF.1.5"><p class="no_margin">Several deep <a class="def" href="/books/n/gene/glossary/def-item/intronic/">intronic</a> pathogenic variants that would not be detected by routine <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> have been reported [<a class="bk_pop" href="#xla.REF.kralovicova.2011.7077">Kralovicova et al 2011</a>, <a class="bk_pop" href="#xla.REF.mohiuddin.2013.1717">Mohiuddin et al 2013</a>, <a class="bk_pop" href="#xla.REF.rattanachartnarong.2014.431">Rattanachartnarong et al 2014</a>]. Pathogenic intronic variants that cause <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> defects may be detected by targeted sequencing or analysis of <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a>.</p></div></dd><dt>6. </dt><dd><div id="xla.TF.1.6"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications. These methods will detect single-exon up to whole-gene deletions; however, breakpoints of large deletions and/or deletion of adjacent genes may not be detected by these methods.</p></div></dd><dt>7. </dt><dd><div id="xla.TF.1.7"><p class="no_margin">Chromosomal microarray analysis (CMA) using oligonucleotide arrays or SNP arrays. CMA designs in current clinical use target the Xq22.1 region.</p></div></dd><dt>8. </dt><dd><div id="xla.TF.1.8"><p class="no_margin">Approximately 3%-5% of individuals (a subset of the 8% detected by <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>) with a <i>BTK</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> have a large deletion that extends through the closely linked gene <i>TIMM8A</i> (also called <i>DDP</i>) and sometimes through <i>TAF7L</i> and <i>DRP2</i> [<a class="bk_pop" href="#xla.REF.richter.2001.107">Richter et al 2001</a>, <a class="bk_pop" href="#xla.REF.sediv_.2007.640">Sediv&#x000e1; et al 2007</a>]. Individuals with these multigene deletions have XLA and <a href="/books/n/gene/ddon/">deafness-dystonia-optic neuropathy syndrome</a> (DDON; also called Mohr-Tranebj&#x000e6;rg syndrome).</p></div></dd></dl></div></div></div></div></div><div id="xla.Clinical_Characteristics"><h2 id="_xla_Clinical_Characteristics_">Clinical Characteristics</h2><div id="xla.Clinical_Description"><h3>Clinical Description</h3><p>Males with <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> agammaglobulinemia (XLA) are usually well for the first few months of life because they are protected by transplacentally acquired maternal immunoglobulin. Typically, <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males develop recurrent bacterial infections in the first two years of life and are recognized as having immunodeficiency before age five years [<a class="bk_pop" href="#xla.REF.ochs.1996.287">Ochs &#x00026; Smith 1996</a>, <a class="bk_pop" href="#xla.REF.conley.2002.566">Conley &#x00026; Howard 2002</a>, <a class="bk_pop" href="#xla.REF.plebani.2002.221">Plebani et al 2002</a>, <a class="bk_pop" href="#xla.REF.winkelstein.2006.193">Winkelstein et al 2006</a>].</p><p>Recurrent otitis is the most common infection prior to diagnosis. Conjunctivitis, sinopulmonary infections, diarrhea, and skin infections are also frequently seen. Approximately 60% of individuals with XLA are recognized as having immunodeficiency when they develop a severe, life-threatening infection such as pneumonia, empyema, meningitis, sepsis, cellulitis, or septic arthritis. Because males with XLA fail to make antibodies to vaccine antigens like tetanus, <i>H influenzae</i>, or <i>S pneumoniae,</i> the latter two organisms are the most commonly seen prior to diagnosis of XLA and they may continue to cause sinusitis and otitis even after diagnosis and the initiation of gammaglobulin substitution therapy [<a class="bk_pop" href="#xla.REF.lederman.1985.145">Lederman &#x00026; Winkelstein 1985</a>, <a class="bk_pop" href="#xla.REF.conley.2005.216">Conley et al 2005</a>].</p><p>Individuals with XLA are not vulnerable to the majority of viral infections; however, they are susceptible to severe and chronic enteroviral infections (often manifesting as dermatomyositis or chronic meningoencephalitis) [<a class="bk_pop" href="#xla.REF.wilfert.1977.1485">Wilfert et al 1977</a>, <a class="bk_pop" href="#xla.REF.bearden.2016.1059">Bearden et al 2016</a>]. In the past, 5%-10% of individuals with XLA developed vaccine-associated polio after vaccination with the live attenuated oral polio vaccine. Since the mid-1980s, when gammaglobulin substitution therapy became available, the incidence of chronic enteroviral infection has markedly decreased in individuals with XLA. However, some individuals still develop enteroviral encephalitis and some have neurologic deterioration of unknown etiology [<a class="bk_pop" href="#xla.REF.misbah.1992.266">Misbah et al 1992</a>, <a class="bk_pop" href="#xla.REF.ziegner.2002.19">Ziegner et al 2002</a>].</p><p>Like all individuals with antibody deficiencies, persons with XLA are highly susceptible to giardia infection. They may also develop persistent mycoplasma infections. Infections with unusual organisms, like <i>Flexispira</i> or <i>Helicobacter cinaedi</i>, may also be troublesome [<a class="bk_pop" href="#xla.REF.cuccherini.2000.121">Cuccherini et al 2000</a>, <a class="bk_pop" href="#xla.REF.simons.2004.367">Simons et al 2004</a>].</p><p>Approximately 10% of males with a <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> <i>BTK</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> are not recognized as having immunodeficiency until after age ten years and some not until adulthood [<a class="bk_pop" href="#xla.REF.howard.2006.201">Howard et al 2006</a>, <a class="bk_pop" href="#xla.REF.conley.2008.39">Conley et al 2008</a>]. Some <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males have higher serum immunoglobulin concentrations than expected, but all have very low numbers of B cells.</p><p>The prognosis for individuals with XLA has improved markedly in the last 35 years [<a class="bk_pop" href="#xla.REF.howard.2006.201">Howard et al 2006</a>] as a result of earlier diagnosis, more liberal use of antibiotics, and the development of preparations of gammaglobulin that allow gammaglobulin substitution therapy to achieve normal concentrations of serum IgG. Most individuals lead a normal life. However, approximately 10% develop significant infections despite appropriate therapy and many have chronic pulmonary changes [<a class="bk_pop" href="#xla.REF.quartier.1999.589">Quartier et al 1999</a>].</p><p><b>Heterozygous females.</b> A single female with XLA has been reported. Her father had XLA and analysis demonstrated exclusive use of the paternally derived X <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> as the active X [<a class="bk_pop" href="#xla.REF.takada.2004.185">Takada et al 2004</a>].</p></div><div id="xla.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>No strong correlation is observed between the specific <i>BTK</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> and the severity of disease; however, individuals who have amino acid substitutions or splice defects that occur at sites that are conserved, but not invariant, tend to be older at the time of diagnosis, and have higher serum concentrations of IgM and slightly more B cells in the peripheral circulation [<a class="bk_pop" href="#xla.REF.l_pezgranados.2005.690">L&#x000f3;pez-Granados et al 2005</a>, <a class="bk_pop" href="#xla.REF.broides.2006.195">Broides et al 2006</a>].</p></div><div id="xla.Nomenclature"><h3>Nomenclature</h3><p>Bruton called the disorder that he first described in 1952 "agammaglobulinemia." The <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> pattern of inheritance was noted shortly after that time.</p><p>In the 50s, 60s, and 70s, the disorder was sometimes called <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> agammaglobulinemia, <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> hypogammaglobulinemia or infantile agammaglobulinemia, or simply agammaglobulinemia.</p></div><div id="xla.Prevalence"><h3>Prevalence</h3><p>Prevalence of <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> agammaglobulinemia is approximately 3:1,000,000-6:1,000,000 males in all racial and ethnic groups.</p></div></div><div id="xla.Genetically_Related_Disorders"><h2 id="_xla_Genetically_Related_Disorders_">Genetically Related Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with pathogenic variants in <i>BTK.</i></p><p>Approximately 3%-5% of individuals with a <i>BTK</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> have a large <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> that extends through the closely linked <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <i>TIMM8A</i> (also called <i>DDP</i>) and sometimes through <i>TAF7L</i> and <i>DRP2</i> [<a class="bk_pop" href="#xla.REF.richter.2001.107">Richter et al 2001</a>, <a class="bk_pop" href="#xla.REF.sediv_.2007.640">Sediv&#x000e1; et al 2007</a>]. Individuals with these multigene deletions have XLA and <a href="/books/n/gene/ddon/">deafness-dystonia-optic neuropathy syndrome</a> (DDON; also called Mohr-Tranebj&#x000e6;rg syndrome).</p></div><div id="xla.Differential_Diagnosis"><h2 id="_xla_Differential_Diagnosis_">Differential Diagnosis</h2><p>Approximately 90% of males who are presumed to have <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> agammaglobulinemia (XLA) based on early onset of infections, severe hypogammaglobulinemia, and markedly reduced numbers of B cells have detectable pathogenic variants in <i>BTK</i> [<a class="bk_pop" href="#xla.REF.conley.1998.1034">Conley et al 1998</a>].</p><p>The majority of females with an XLA-like <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> and males with an XLA phenotype who do not have an identifiable <i>BTK</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> are likely to have defects in other genes required for normal B-cell development (see <a href="http://omim.org/phenotypicSeries/PS601495" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Agammaglobulinemia: OMIM Phenotypic Series</a> to view genes associated with agammaglobulinemia in OMIM). These <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> forms of agammaglobulinemia are very rare.</p><ul><li class="half_rhythm"><div>At least thirty individuals with more than 20 different pathogenic variants in <i>IGHM</i> (encoding Ig &#x003bc; chain C region) have been reported [<a class="bk_pop" href="#xla.REF.lopez_granados.2002.1029">Lopez Granados et al 2002</a>, <a class="bk_pop" href="#xla.REF.ferrari.2007b.325">Ferrari et al 2007b</a>, <a class="bk_pop" href="#xla.REF.van_zelm.2008.320">van Zelm et al 2008</a>]. These individuals tend to come to medical attention at an earlier age and are more likely to have life-threatening infections than individuals with XLA, but clinical overlap is considerable.</div></li><li class="half_rhythm"><div>Defects in Ig&#x003b1; (<i>CD79A</i>), Ig&#x003b2; (<i>CD79B</i>), &#x003bb;5 (<i>IGLL1</i>), <i>BLNK</i>, or <i>PIK3R1</i> have been reported in fewer than five individuals each. Individuals with any of these five genetic defects cannot be distinguished by routine clinical or laboratory tests from individuals with XLA [<a class="bk_pop" href="#xla.REF.conley.2005.216">Conley et al 2005</a>, <a class="bk_pop" href="#xla.REF.dobbs.2007.2055">Dobbs et al 2007</a>, <a class="bk_pop" href="#xla.REF.ferrari.2007a.2047">Ferrari et al 2007a</a>, <a class="bk_pop" href="#xla.REF.conley.2012.463">Conley et al 2012</a>, <a class="bk_pop" href="#xla.REF.bergl_f.2013.1205">Bergl&#x000f6;f et al 2013</a>].</div></li></ul><p>These disorders should be considered in females who have an XLA-like <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> or in males who were presumed to have XLA but who do not have a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>BTK.</i> Families with a known history of <a class="def" href="/books/n/gene/glossary/def-item/consanguinity/">consanguinity</a> are more likely to have rare <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> forms of agammaglobulinemia than XLA.</p><p>The underlying defect remains unknown in approximately 5% of individuals with <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> agammaglobulinemia and absent B cells.</p><p>Low concentrations of serum immunoglobulins can be seen in a variety of conditions, including the following <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> disorders:</p><ul><li class="half_rhythm"><div><a href="/books/n/gene/xlhi/">X-linked hyper IgM syndrome</a> (also known as CD40 ligand deficiency)</div></li><li class="half_rhythm"><div><a href="/books/n/gene/x-scid/">X-linked severe combined immunodeficiency</a></div></li><li class="half_rhythm"><div><a href="/books/n/gene/x-lpd/">X-linked lymphoproliferative disease</a></div></li></ul><p>However, individuals with these disorders usually have relatively normal or elevated numbers of B cells.</p></div><div id="xla.Management"><h2 id="_xla_Management_">Management</h2><div id="xla.Evaluations_Following_Initial_Diagno"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs of an individual diagnosed with <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> agammaglobulinemia (XLA), the following evaluations are recommended:</p><ul><li class="half_rhythm"><div>A complete blood count with differential</div></li><li class="half_rhythm"><div>Chemistries that include renal and liver function tests, total protein, albumin, and CRP</div></li><li class="half_rhythm"><div>Quantitative serum immunoglobulins and titers to vaccine antigens as baseline measurements prior to initiation of gammaglobulin substitution therapy</div></li><li class="half_rhythm"><div>Baseline chest and sinus x-rays</div></li><li class="half_rhythm"><div>If the patient is able to cooperate, base line pulmonary function tests</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="xla.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>Individuals with XLA should receive specialty care at a center with expertise in this disorder.</p><p>If individuals develop acute infections, they should be treated with a course of antibiotics that is at least twice as long as that used in otherwise healthy individuals. Generous use of antibiotics is recommended and treatment should be given without any unnecessary delay.</p></div><div id="xla.Prevention_of_Primary_Manifestations"><h3>Prevention of Primary Manifestations</h3><div id="xla.Bacterial_Infections"><h4>Bacterial Infections</h4><p><b>Gammaglobulin substitution</b> therapy is the mainstay of treatment for individuals with XLA. Most individuals in the United States are given approximately 400 mg/kg of gammaglobulin every four weeks. In the past, the majority of individuals received their gammaglobulin by intravenous infusion every two to four weeks. In the last few years, an increasing proportion of individuals have been receiving gammaglobulin by weekly subcutaneous injections. Both routes provide good therapeutic concentrations of serum IgG. The choice of route may depend on factors related to the convenience of the physician and patient [<a class="bk_pop" href="#xla.REF.berger.2004.1">Berger 2004</a>].</p><p>A variety of brands of gammaglobulin are available; none has proven to be superior to others as measured by efficacy or side effects. Occasionally, individuals with XLA have a reaction to gammaglobulin, consisting of headaches, chills, backache, or nausea. These reactions are more likely to occur when the individual has an intercurrent viral infection or when the brand of gammaglobulin has been changed. Such reactions may disappear over time.</p><p><b>Chronic prophylactic antibiotics</b> are used in some centers for prevention of bacterial infections.</p></div></div><div id="xla.Prevention_of_Secondary_Complication"><h3>Prevention of Secondary Complications</h3><p>Children with XLA should only be given inactivated polio vaccine (IPV) and not oral polio vaccine.</p><p>The sibs of children with XLA should also be given IPV rather than oral polio vaccine (in order to avoid infecting their <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> sib with live virus).</p></div><div id="xla.Surveillance"><h3>Surveillance</h3><p>At least once a year:</p><ul><li class="half_rhythm"><div class="half_rhythm">A complete blood count with differential, chemistries, and quantitative serum immunoglobulins to monitor gammaglobulin substitution therapy</div></li><li class="half_rhythm"><div class="half_rhythm">Chest x-rays or CTs and sinus films</div><div class="half_rhythm">Note: Chronic lung disease can develop in the absence of an acute pulmonary infection [<a class="bk_pop" href="#xla.REF.quartier.1999.589">Quartier et al 1999</a>].</div></li></ul><p>If the patient is stable, the serum IgG does not need to be evaluated with every infusion of gammaglobulin.</p></div><div id="xla.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Live viral vaccines, particularly oral polio vaccine, should be avoided in individuals with XLA.</p></div><div id="xla.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to evaluate at-risk male relatives as soon after birth as possible so that gammaglobulin substitution therapy can be initiated promptly and administration of live viral vaccines can be avoided. Evaluations can include:</p><ul><li class="half_rhythm"><div>Molecular genetic testing for the known family-specific <i>BTK</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>;</div></li><li class="half_rhythm"><div>Analysis of the percentage of B cells in the peripheral circulation.</div></li></ul><p>Note: Serum immunoglobulins will not be helpful in the evaluation of a newborn or infant because maternal IgG crosses the placenta.</p><p>See <a href="#xla.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="xla.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Research studies exploring <a class="def" href="/books/n/gene/glossary/def-item/gene-therapy/">gene therapy</a> for XLA have been conducted in mice [<a class="bk_pop" href="#xla.REF.kerns.2010.2146">Kerns et al 2010</a>, <a class="bk_pop" href="#xla.REF.ng.2010.1617">Ng et al 2010</a>, <a class="bk_pop" href="#xla.REF.bestas.2014.4067">Bestas et al 2014</a>], but it is not clear when this type of treatment may be available for humans.</p><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="xla.Genetic_Counseling"><h2 id="_xla_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="xla.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p><a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> agammaglobulinemia is inherited in an X-linked manner.</p></div><div id="xla.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The father of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male will not have the disorder nor will he be <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> for the <i>BTK</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>; therefore, he does not require further evaluation/testing.</div></li><li class="half_rhythm"><div>In a family with more than one <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual, the mother of an affected male is an <a class="def" href="/books/n/gene/glossary/def-item/obligate-heterozygote/">obligate heterozygote</a> (<a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>).</div></li><li class="half_rhythm"><div>If a woman has more than one <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child and no other affected relatives and if the <i>BTK</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> cannot be detected in her leukocyte DNA, she has <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>. Germline mosaicism has been observed [<a class="bk_pop" href="#xla.REF.sakamoto.2001.234">Sakamoto et al 2001</a>].</div></li><li class="half_rhythm"><div>If an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male is the only affected family member (50% of affected males represent <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases), there are two possibilities:</div><ul><li class="half_rhythm"><div>The mother is a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> (~80%-85% of cases).</div></li><li class="half_rhythm"><div>The <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male has a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, in which case the mother is not a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> (~15%-20% of cases)</div></li></ul></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The risk to sibs depends on the genetic status of the mother.</div></li><li class="half_rhythm"><div>If the mother is a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, the chance of transmitting the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in each pregnancy is 50%. Males who inherit the pathogenic variant will be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>; females who inherit the pathogenic variant will be carriers and are highly unlikely to be affected.</div></li><li class="half_rhythm"><div>Germline <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a> has been observed [<a class="bk_pop" href="#xla.REF.sakamoto.2001.234">Sakamoto et al 2001</a>]. Thus, if an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male represents a single case in a family and if the <i>BTK</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> cannot be detected in the leukocyte DNA of his mother, the male sibs are still at increased risk (&#x0003c;5%) of being affected.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Affected males transmit the <i>BTK</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> to:</p><ul><li class="half_rhythm"><div>All of their daughters, who will be carriers and are not likely to be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>;</div></li><li class="half_rhythm"><div>None of their sons.</div></li></ul><p><b>Other family members</b></p><ul><li class="half_rhythm"><div>A male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s maternal aunts may be at risk of being heterozygotes (carriers) for the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> and the aunts&#x02019; offspring, depending on their gender, may be at risk of being heterozygotes (carriers) for the pathogenic variant or of being <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>.</div></li><li class="half_rhythm"><div>Linkage analysis has shown that the maternal grandfather is the source of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the majority of males who have no family history of XLA and that the maternal grandmothers are carriers less than 20% of the time [<a class="bk_pop" href="#xla.REF.conley.1998.1034">Conley et al 1998</a>]. Therefore, the risk that the maternal aunt of a boy with no family history of XLA is a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> is less than 10%.</div></li></ul></div><div id="xla.Heterozygote_Carrier_Detection"><h3>Heterozygote (Carrier) Detection</h3><p>Molecular genetic testing of at-risk female relatives to determine their genetic status is most informative if the <i>BTK</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</p><p>Note: (1) Females who are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> (carriers) for this <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> disorder are not likely to be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>. (2) Identification of female heterozygotes requires either (a) prior identification of the <i>BTK</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family or, (b) if an affected male is not available for testing, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> first by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, and if no pathogenic variant is identified, by <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>.</p></div><div id="xla.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#xla.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="xla.Prenatal_Testing_and_Preimplantation"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>BTK</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> agammaglobulinemia are possible.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="xla.Resources"><h2 id="_xla_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Canadian Immunodeficiencies Patient Organization (CIPO)</b></div><div>362 Concession Road 12</div><div>RR #2</div><div>Hastings Ontario K0L 1Y0</div><div>Canada</div><div><b>Phone:</b> 877-262-2476 (toll-free)</div><div><b>Fax:</b> 866-942-7651 (toll-free)</div><div><b>Email:</b> info@cipo.ca</div><div><a href="http://cipo.ca" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.cipo.ca</a></div></li><li class="half_rhythm"><div><b>Jeffrey Modell Foundation/National Primary Immunodeficiency Resource Center</b></div><div>747 Third Avenue</div><div>New York NY 10017</div><div><b>Phone:</b> 866-463-6474 (toll-free); 212-819-0200</div><div><b>Fax:</b> 212-764-4180</div><div><b>Email:</b> info@jmfworld.org</div><div><a href="http://www.info4pi.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.info4pi.org</a></div></li><li class="half_rhythm"><div><b>European Society for Immunodeficiencies (ESID) Registry</b></div><div>Dr. Gerhard Kindle</div><div>University Medical Center Freiburg Centre of Chronic Immunodeficiency</div><div>Engesserstr. 4</div><div>79106 Freiburg </div><div>Germany</div><div><b>Phone:</b> 49-761-270-34450</div><div><b>Email:</b> esid-registry@uniklinik-freiburg.de</div><div><a href="http://esid.org/Working-Parties/Registry" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ESID Registry</a></div></li><li class="half_rhythm"><div><b>Primary Immunodeficiency Diseases Registry at USIDNET</b></div><div>40 West Chesapeake Avenue</div><div>Suite 308</div><div>Towson MD 21204-4803</div><div><b>Phone:</b> 866-939-7568</div><div><b>Fax:</b> 410-321-0293</div><div><b>Email:</b> contact@usidnet.org</div><div><a href="http://usidnet.org/usidnet-registry/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Primary Immunodeficiency Registry at USIDNET</a></div></li></ul></div><div id="xla.Molecular_Genetics"><h2 id="_xla_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="xla.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>X-Linked Agammaglobulinemia: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1453/table/xla.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__xla.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_xla.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_xla.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_xla.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_xla.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_xla.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_xla.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_xla.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/695" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>BTK</i></a></td><td headers="hd_b_xla.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=695" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Xq22<wbr style="display:inline-block"></wbr>​.1</a></td><td headers="hd_b_xla.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q06187" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Tyrosine-protein kinase BTK</a></td><td headers="hd_b_xla.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.LOVD.nl/BTK" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">BTK @ LOVD</a><br /><a href="http://structure.bmc.lu.se/idbase/BTKbase/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">BTK base: Mutation registry for X-linked agammaglobulinemia</a></td><td headers="hd_b_xla.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=BTK" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">BTK</a></td><td headers="hd_b_xla.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=BTK[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">BTK</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="xla.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="xla.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for X-Linked Agammaglobulinemia (<a href="/omim/300300,300755" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1453/table/xla.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__xla.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/300300" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">300300</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE; BTK</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/300755" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">300755</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">AGAMMAGLOBULINEMIA, X-LINKED; XLA</td></tr></tbody></table></div></div><p><b>Gene structure.</b>
<i>BTK</i> has 19 exons spread over 37 kb based on reference sequence <a href="/nuccore/NM_000061.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000061.2</a> [<a class="bk_pop" href="#xla.REF.sideras.1994.5607">Sideras et al 1994</a>]. See <a href="/books/NBK1453/#xla.molgen.TA">Table A</a>, <b>Gene</b> for a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information.</p><p><b>Pathogenic variants.</b> More than 600 different pathogenic variants in <i>BTK</i> have been reported, and no single <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> accounts for more than 3% of individuals [<a class="bk_pop" href="#xla.REF.holinskifeder.1998.276">Holinski-Feder et al 1998</a>, <a class="bk_pop" href="#xla.REF.vihinen.1999.280">Vihinen et al 1999</a>, <a class="bk_pop" href="#xla.REF.conley.2005.216">Conley et al 2005</a>, <a class="bk_pop" href="#xla.REF.lindvall.2005.200">Lindvall et al 2005</a>, <a class="bk_pop" href="#xla.REF.v_liaho.2006.1209">V&#x000e4;liaho et al 2006</a>, <a class="bk_pop" href="#xla.REF.v_liaho.2015.638">V&#x000e4;liaho et al 2015</a>].</p><p>Two thirds of pathogenic variants are premature stop codons, splice defects, or frameshift variants. These variants result in improper processing of the <i>BTK</i> message. Therefore, no <i>BTK</i> message can be identified in the cytoplasm.</p><p>Approximately one third of pathogenic variants are amino acid substitutions; however, approximately two thirds of these pathogenic variants appear to make the protein unstable (for more information, see <a href="/books/NBK1453/#xla.molgen.TA">Table A</a>).</p><p>Several deep <a class="def" href="/books/n/gene/glossary/def-item/intronic/">intronic</a> pathogenic variants that would not be detected by routine <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> have been reported [<a class="bk_pop" href="#xla.REF.kralovicova.2011.7077">Kralovicova et al 2011</a>, <a class="bk_pop" href="#xla.REF.mohiuddin.2013.1717">Mohiuddin et al 2013</a>, <a class="bk_pop" href="#xla.REF.rattanachartnarong.2014.431">Rattanachartnarong et al 2014</a>].</p><p>Approximately 3%-5% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals who have a large <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> that extends through neighboring genes have XLA and <a href="/books/n/gene/ddon/">deafness-dystonia-optic neuropathy syndrome</a> (DDON, also called Mohr-Tranebj&#x000e6;rg syndrome; see <a href="#xla.Genetically_Related_Disorders">Genetically Related Disorders</a>).</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The normal <i>BTK</i> product has 659 amino acid residues and is expressed in hematopoietic progenitors, myeloid cells and platelets, and B lineage cells [RefSeq <a href="/entrez/viewer.fcgi?val=NP_000052.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000052.1</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The protein is absent in more than 85% of individuals with XLA.</p></div><div id="xla.References"><h2 id="_xla_References_">References</h2><div id="xla.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="xla.REF.bearden.2016.1059">Bearden D, Collett M, Quan PL, Costa-Carvalho BT, Sullivan KE. Enteroviruses in X-linked agammaglobulinemia: update on epidemiology and therapy. <span><span class="ref-journal">J Allergy Clin Immunol Pract. </span>2016;<span class="ref-vol">4</span>:1059–65.</span> [<a href="/pubmed/26883540" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26883540</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xla.REF.berger.2004.1">Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. <span><span class="ref-journal">Clin Immunol. </span>2004;<span class="ref-vol">112</span>:1–7.</span> [<a href="/pubmed/15207776" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15207776</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xla.REF.bergl_f.2013.1205">Bergl&#x000f6;f A, Turunen JJ, Gissberg O, Bestas B, Blomberg KE, Smith CI. Agammaglobulinemia: causative mutations and their implications for novel therapies. <span><span class="ref-journal">Expert Rev Clin Immunol. </span>2013;<span class="ref-vol">9</span>:1205–21.</span> [<a href="/pubmed/24215410" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24215410</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xla.REF.bestas.2014.4067">Bestas B, Moreno PM, Blomberg KE, Mohammad DK, Saleh AF, Sutlu T, Nordin JZ, Guterstam P, Gustafsson MO, Kharazi S, Pi&#x00105;tosa B, Roberts TC, Behlke MA, Wood MJ, Gait MJ, Lundin KE, El Andaloussi S, M&#x000e5;nsson R, Bergl&#x000f6;f A, Wengel J, Smith CI. Splice-correcting oligonucleotides restore BTK function in X-linked agammaglobulinemia model. <span><span class="ref-journal">J Clin Invest. </span>2014;<span class="ref-vol">124</span>:4067–81.</span> [<a href="/pmc/articles/PMC4151202/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4151202</span></a>] [<a href="/pubmed/25105368" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25105368</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xla.REF.broides.2006.195">Broides A, Yang W, Conley ME. Genotype/phenotype correlations in X-linked agammaglobulinemia. <span><span class="ref-journal">Clin Immunol. </span>2006;<span class="ref-vol">118</span>:195–200.</span> [<a href="/pubmed/16297664" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16297664</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xla.REF.conley.1985.3070">Conley ME. B cells in patients with X-linked agammaglobulinemia. <span><span class="ref-journal">J Immunol. </span>1985;<span class="ref-vol">134</span>:3070–4.</span> [<a href="/pubmed/3920309" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3920309</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xla.REF.conley.2005.216">Conley ME, Broides A, Hernandez-Trujillo V, Howard V, Kanegane H, Miyawaki T, Shurtleff SA. Genetic analysis of patients with defects in early B-cell development. <span><span class="ref-journal">Immunol Rev. </span>2005;<span class="ref-vol">203</span>:216–34.</span> [<a href="/pubmed/15661032" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15661032</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xla.REF.conley.2012.463">Conley ME, Dobbs AK, Quintana AM, Bosompem A, Wang YD, Coustan-Smith E, Smith AM, Perez EE, Murray PJ. Agammaglobulinemia and absent B lineage cells in a patient lacking the p85&#x003b1; subunit of PI3K. <span><span class="ref-journal">J Exp Med. </span>2012;<span class="ref-vol">209</span>:463–70.</span> [<a href="/pmc/articles/PMC3302225/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3302225</span></a>] [<a href="/pubmed/22351933" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22351933</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xla.REF.conley.2008.39">Conley ME, Farmer DM, Dobbs AK, Howard V, Aiba Y, Shurtleff SA, Kurosaki T. A minimally hypomorphic mutation in Btk resulting in reduced B cell numbers but no clinical disease. <span><span class="ref-journal">Clin Exp Immunol. </span>2008;<span class="ref-vol">152</span>:39–44.</span> [<a href="/pmc/articles/PMC2384053/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2384053</span></a>] [<a href="/pubmed/18241230" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18241230</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xla.REF.conley.2002.566">Conley ME, Howard V. Clinical findings leading to the diagnosis of X-linked agammaglobulinemia. <span><span class="ref-journal">J Pediatr. </span>2002;<span class="ref-vol">141</span>:566–71.</span> [<a href="/pubmed/12378199" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12378199</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xla.REF.conley.1998.1034">Conley ME, Mathias D, Treadaway J, Minegishi Y, Rohrer J. Mutations in BTK in patients with presumed X-linked agammaglobulinemia. <span><span class="ref-journal">Am J Hum Genet. </span>1998;<span class="ref-vol">62</span>:1034–43.</span> [<a href="/pmc/articles/PMC1377085/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1377085</span></a>] [<a href="/pubmed/9545398" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9545398</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xla.REF.cuccherini.2000.121">Cuccherini B, Chua K, Gill V, Weir S, Wray B, Stewart D, Nelson D, Fuss I, Strober W. Bacteremia and skin/bone infections in two patients with X-linked agammaglobulinemia caused by an unusual organism related to Flexispira/Helicobacter species. <span><span class="ref-journal">Clin Immunol. </span>2000;<span class="ref-vol">97</span>:121–9.</span> [<a href="/pubmed/11027452" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11027452</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xla.REF.dobbs.2007.2055">Dobbs AK, Yang T, Farmer D, Kager L, Parolini O, Conley ME. Cutting edge: a hypomorphic mutation in Igbeta (CD79b) in a patient with immunodeficiency and a leaky defect in B cell development. <span><span class="ref-journal">J Immunol. </span>2007;<span class="ref-vol">179</span>:2055–9.</span> [<a href="/pubmed/17675462" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17675462</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xla.REF.ferrari.2007a.2047">Ferrari S, Lougaris V, Caraffi S, Zuntini R, Yang J, Soresina A, Meini A, Cazzola G, Rossi C, Reth M, Plebani A. Mutations of the Igbeta gene cause agammaglobulinemia in man. <span><span class="ref-journal">J Exp Med. </span>2007a;<span class="ref-vol">204</span>:2047–51.</span> [<a href="/pmc/articles/PMC2118692/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2118692</span></a>] [<a href="/pubmed/17709424" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17709424</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xla.REF.ferrari.2007b.325">Ferrari S, Zuntini R, Lougaris V, Soresina A, Sourkov&#x000e1; V, Fiorini M, Martino S, Rossi P, Pietrogrande MC, Martire B, Spadaro G, Cardinale F, Cossu F, Pierani P, Quinti I, Rossi C, Plebani A. Molecular analysis of the pre-BCR complex in a large cohort of patients affected by autosomal-recessive agammaglobulinemia. <span><span class="ref-journal">Genes Immun. </span>2007b;<span class="ref-vol">8</span>:325–33.</span> [<a href="/pubmed/17410177" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17410177</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xla.REF.holinskifeder.1998.276">Holinski-Feder E, Weiss M, Brandau O, Jedele KB, Nore B, Backesjo CM, Vihinen M, Hubbard SR, Belohradsky BH, Smith CI, Meindl A. Mutation screening of the BTK gene in 56 families with X-linked agammaglobulinemia (XLA): 47 unique mutations without correlation to clinical course. <span><span class="ref-journal">Pediatrics. </span>1998;<span class="ref-vol">101</span>:276–84.</span> [<a href="/pubmed/9445504" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9445504</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xla.REF.howard.2006.201">Howard V, Greene JM, Pahwa S, Winkelstein JA, Boyle JM, Kocak M, Conley ME. The health status and quality of life of adults with X-linked agammaglobulinemia. <span><span class="ref-journal">Clin Immunol. </span>2006;<span class="ref-vol">118</span>:201–8.</span> [<a href="/pubmed/16377251" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16377251</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xla.REF.kerns.2010.2146">Kerns HM, Ryu BY, Stirling BV, Sather BD, Astrakhan A, Humblet-Baron S, Liggitt D, Rawlings DJ. B cell-specific lentiviral gene therapy leads to sustained B-cell functional recovery in a murine model of X-linked agammaglobulinemia. <span><span class="ref-journal">Blood. </span>2010;<span class="ref-vol">115</span>:2146–55.</span> [<a href="/pmc/articles/PMC2844021/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2844021</span></a>] [<a href="/pubmed/20093406" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20093406</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xla.REF.kralovicova.2011.7077">Kralovicova J, Hwang G, Asplund AC, Churbanov A, Smith CIE, Vorechovsky I. Compensatory signals associated with the activation of human GC 5' splice sites. <span><span class="ref-journal">Nucleic Acids Res. </span>2011;<span class="ref-vol">39</span>:7077–91.</span> [<a href="/pmc/articles/PMC3167603/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3167603</span></a>] [<a href="/pubmed/21609956" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21609956</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xla.REF.lederman.1985.145">Lederman HM, Winkelstein JA. X-linked agammaglobulinemia: an analysis of 96 patients. <span><span class="ref-journal">Medicine (Baltimore). </span>1985;<span class="ref-vol">64</span>:145–56.</span> [<a href="/pubmed/2581110" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2581110</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xla.REF.lindvall.2005.200">Lindvall JM, Blomberg KE, Valiaho J, Vargas L, Heinonen JE, Berglof A, Mohamed AJ, Nore BF, Vihinen M, Smith CI. Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling. <span><span class="ref-journal">Immunol Rev. </span>2005;<span class="ref-vol">203</span>:200–15.</span> [<a href="/pubmed/15661031" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15661031</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xla.REF.l_pezgranados.2005.690">L&#x000f3;pez-Granados E, P&#x000e9;rez de Diego R, Ferreira Cerd&#x000e1;n A, Font&#x000e1;n Casariego G, Garc&#x000ed;a Rodr&#x000ed;guez MC. A genotype-phenotype correlation study in a group of 54 patients with X-linked agammaglobulinemia. <span><span class="ref-journal">J.Allergy Clin.Immunol. </span>2005;<span class="ref-vol">116</span>:690–7.</span> [<a href="/pubmed/16159644" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16159644</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xla.REF.lopez_granados.2002.1029">Lopez Granados E, Porpiglia AS, Hogan MB, Matamoros N, Krasovec S, Pignata C, Smith CI, Hammarstrom L, Bjorkander J, Belohradsky BH, Casariego GF, Garcia Rodriguez MC, Conley ME. Clinical and molecular analysis of patients with defects in micro heavy chain gene. <span><span class="ref-journal">J Clin Invest. </span>2002;<span class="ref-vol">110</span>:1029–35.</span> [<a href="/pmc/articles/PMC151150/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC151150</span></a>] [<a href="/pubmed/12370281" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12370281</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xla.REF.misbah.1992.266">Misbah SA, Spickett GP, Ryba PC, Hockaday JM, Kroll JS, Sherwood C, Kurtz JB, Moxon ER, Chapel HM. Chronic enteroviral meningoencephalitis in agammaglobulinemia: case report and literature review. <span><span class="ref-journal">J Clin Immunol. </span>1992;<span class="ref-vol">12</span>:266–70.</span> [<a href="/pubmed/1512300" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1512300</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xla.REF.mohiuddin.2013.1717">Mohiuddin MS, Abbott JK, Hubbard N, Torgerson TR, Ochs HD, Gelfand EW. Diagnosis and evaluation of primary panhypogammaglobulinemia: a molecular and genetic challenge. <span><span class="ref-journal">J Allergy Clin Immunol. </span>2013;<span class="ref-vol">131</span>:1717–8.</span> [<a href="/pubmed/23726535" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23726535</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xla.REF.ng.2010.1617">Ng YY, Baert MR, Pike-Overzet K, Rodijk M, Brugman MH, Schambach A, Baum C, Hendriks RW, van Dongen JJ, Staal FJ. Correction of B-cell development in Btk-deficient mice using lentiviral vectorswith codon-optimized human BTK. <span><span class="ref-journal">Leukemia. </span>2010;<span class="ref-vol">24</span>:1617–30.</span> [<a href="/pubmed/20574453" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20574453</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xla.REF.nonoyama.1998.3925">Nonoyama S, Tsukada S, Yamadori T, Miyawaki T, Jin YZ, Watanabe C, Morio T, Yata J, Ochs HD. Functional analysis of peripheral blood B cells in patients with X-linked agammaglobulinemia. <span><span class="ref-journal">J Immunol. </span>1998;<span class="ref-vol">161</span>:3925–9.</span> [<a href="/pubmed/9780159" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9780159</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xla.REF.ochs.1996.287">Ochs HD, Smith CI. X-linked agammaglobulinemia. A clinical and molecular analysis. <span><span class="ref-journal">Medicine (Baltimore). </span>1996;<span class="ref-vol">75</span>:287–99.</span> [<a href="/pubmed/8982147" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8982147</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xla.REF.plebani.2002.221">Plebani A, Soresina A, Rondelli R, Amato GM, Azzari C, Cardinale F, Cazzola G, Consolini R, De Mattia D, Dell'Erba G, Duse M, Fiorini M, Martino S, Martire B, Masi M, Monafo V, Moschese V, Notarangelo LD, Orlandi P, Panei P, Pession A, Pietrogrande MC, Pignata C, Quinti I, Ragno V, Rossi P, Sciotto A, Stabile A., Italian Pediatric Group for XLA-AIEOP.  Clinical, immunological, and molecular analysis in a large cohort of patiens with X-linked agammaglobulinemia: an Italian multicenter study. <span><span class="ref-journal">Clin Immunol. </span>2002;<span class="ref-vol">104</span>:221–30.</span> [<a href="/pubmed/12217331" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12217331</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xla.REF.quartier.1999.589">Quartier P, Debre M, De Blic J, de Sauverzac R, Sayegh N, Jabado N, Haddad E, Blanche S, Casanova JL, Smith CI, Le Deist F, de Saint Basile G, Fischer A. Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients. <span><span class="ref-journal">J Pediatr. </span>1999;<span class="ref-vol">134</span>:589–96.</span> [<a href="/pubmed/10228295" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10228295</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xla.REF.rattanachartnarong.2014.431">Rattanachartnarong N, Tongkobpetch S, Chatchatee P, Daengsuwan T, Ittiwut C, Suphapeetiporn K, Shotelersuk V. In vitro correction of a novel splicing alteration in the BTK gene by using antisense morpholino oligonucleotides. <span><span class="ref-journal">Arch Immunol Ther Exp (Warsz). </span>2014;<span class="ref-vol">62</span>:431–6.</span> [<a href="/pubmed/24658450" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24658450</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xla.REF.richter.2001.107">Richter D, Conley ME, Rohrer J, Myers LA, Zahradka K, Kelecic J, Sertic J, Stavljenic-Rukavina A. A contiguous deletion syndrome of X-linked agammaglobulinemia and sensorineural deafness. <span><span class="ref-journal">Pediatr Allergy Immunol. </span>2001;<span class="ref-vol">12</span>:107–11.</span> [<a href="/pubmed/11338284" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11338284</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xla.REF.sakamoto.2001.234">Sakamoto M, Kanegane H, Fujii H, Tsukada S, Miyawaki T, Shinomiya N. Maternal germinal mosaicism of X-linked agammaglobulinemia. <span><span class="ref-journal">Am J Med Genet. </span>2001;<span class="ref-vol">99</span>:234–7.</span> [<a href="/pubmed/11241495" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11241495</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xla.REF.sediv_.2007.640">Sediv&#x000e1; A, Smith CI, Asplund AC, Hadac J, Janda A, Zeman J, Hans&#x000ed;kov&#x000e1; H, Dvor&#x000e1;kov&#x000e1; L, Mr&#x000e1;zov&#x000e1; L, Velbri S, Koehler C, Roesch K, Sullivan KE, Futatani T, Ochs HD. Contiguous X-chromosome deletion syndrome encompassing the BTK, TIMM8A, TAF7L, and DRP2 genes. <span><span class="ref-journal">J Clin Immunol. </span>2007;<span class="ref-vol">27</span>:640–6.</span> [<a href="/pubmed/17851739" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17851739</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xla.REF.sideras.1994.5607">Sideras P, M&#x000fc;ller S, Shiels H, Jin H, Khan WN, Nilsson L, Parkinson E, Thomas JD, Brand&#x000e9;n L, Larsson I. Genomic organization of mouse and human Bruton's agammaglobulinemia tyrosine kinase (Btk) loci. <span><span class="ref-journal">J Immunol. </span>1994;<span class="ref-vol">153</span>:5607–17.</span> [<a href="/pubmed/7989760" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7989760</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xla.REF.simons.2004.367">Simons E, Spacek LA, Lederman HM, Winkelstein JA. Helicobacter cinaedi bacteremia presenting as macules in an afebrile patient with X-linked agammaglobulinemia. <span><span class="ref-journal">Infection. </span>2004;<span class="ref-vol">32</span>:367–8.</span> [<a href="/pubmed/15597229" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15597229</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xla.REF.takada.2004.185">Takada H, Kanegane H, Nomura A, Yamamoto K, Ihara K, Takahashi Y, Tsukada S, Miyawaki T, Hara T. Female agammaglobulinemia due to the Bruton tyrosine kinase deficiency caused by extremely skewed X-chromosome inactivation. <span><span class="ref-journal">Blood. </span>2004;<span class="ref-vol">103</span>:185–7.</span> [<a href="/pubmed/12958074" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12958074</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xla.REF.v_liaho.2015.638">V&#x000e4;liaho J, Faisal I, Ortutay C, Smith CI, Vihinen M. Characterization of all possible single-nucleotide change caused amino acid substitutions in the kinase domain of Bruton tyrosine kinase. <span><span class="ref-journal">Hum Mutat. </span>2015;<span class="ref-vol">36</span>:638–47.</span> [<a href="/pubmed/25777788" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25777788</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xla.REF.v_liaho.2006.1209">V&#x000e4;liaho J, Smith CI, Vihinen M. BTKbase: the mutation database for X-linked agammaglobulinemia. <span><span class="ref-journal">Hum Mutat. </span>2006;<span class="ref-vol">27</span>:1209–17.</span> [<a href="/pubmed/16969761" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16969761</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xla.REF.van_zelm.2008.320">van Zelm MC, Geertsema C, Nieuwenhuis N, de Ridder D, Conley ME, Schiff C, Tezcan I, Bernatowska E, Hartwig NG, Sanders EA, Litzman J, Kondratenko I, van Dongen JJ, van der Burg M. Gross deletions involving IGHM, BTK, or Artemis: a model for genomic lesions mediated by transposable elements. <span><span class="ref-journal">Am J Hum Genet. </span>2008;<span class="ref-vol">82</span>:320–32.</span> [<a href="/pmc/articles/PMC2427306/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2427306</span></a>] [<a href="/pubmed/18252213" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18252213</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xla.REF.vihinen.1999.280">Vihinen M, Kwan SP, Lester T, Ochs HD, Resnick I, V&#x000e4;liaho J, Conley ME, Smith CI. Mutations of the human BTK gene coding for bruton tyrosine kinase in X-linked agammaglobulinemia. <span><span class="ref-journal">Hum Mutat. </span>1999;<span class="ref-vol">13</span>:280–5.</span> [<a href="/pubmed/10220140" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10220140</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xla.REF.wilfert.1977.1485">Wilfert CM, Buckley RH, Mohanakumar T, Griffith JF, Katz SL, Whisnant JK, Eggleston PA, Moore M, Treadwell E, Oxman MN, Rosen FS. Persistent and fatal central-nervous-system ECHOvirus infections in patients with agammaglobulinemia. <span><span class="ref-journal">N Engl J Med. </span>1977;<span class="ref-vol">296</span>:1485–9.</span> [<a href="/pubmed/301244" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 301244</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xla.REF.winkelstein.2006.193">Winkelstein JA, Marino MC, Lederman HM, Jones SM, Sullivan K, Burks AW, Conley ME, Cunningham-Rundles C, Ochs HD. X-linked agammaglobulinemia: report on a United States registry of 201 patients. <span><span class="ref-journal">Medicine (Baltimore). </span>2006;2006;<span class="ref-vol">85</span>:193–202.</span> [<a href="/pubmed/16862044" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16862044</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="xla.REF.ziegner.2002.19">Ziegner UH, Kobayashi RH, Cunningham-Rundles C, Espa&#x000f1;ol T, Fasth A, Huttenlocher A, Krogstad P, Marthinsen L, Notarangelo LD, Pasic S, Rieger CH, Rudge P, Sankar R, Shigeoka AO, Stiehm ER, Sullivan KE, Webster AD, Ochs HD. Progressive neurodegeneration in patients with primary immunodeficiency disease on IVIG treatment. <span><span class="ref-journal">Clin Immunol. </span>2002;<span class="ref-vol">102</span>:19–24.</span> [<a href="/pubmed/11781063" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11781063</span></a>]</div></li></ul></div></div><div id="xla.Chapter_Notes"><h2 id="_xla_Chapter_Notes_">Chapter Notes</h2><div id="xla.Author_History"><h3>Author History</h3><p>Mary Ellen Conley, MD; St Jude Children&#x02019;s Research Hospital (2001-2016)<br />Vanessa C Howard, RN, MSN; St Jude Children&#x02019;s Research Hospital (2001-2016)<br />CI Edvard Smith, MD, PhD (2016-present)<br />Anna Bergl&#x000f6;f, PhD (2016-present)</p></div><div id="xla.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>4 August 2016 (bp) Comprehensive update posted live</div></li><li class="half_rhythm"><div>17 November 2011 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>30 July 2009 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>21 December 2005 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>4 November 2004 (mec) Revision: test availability</div></li><li class="half_rhythm"><div>3 October 2003 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>5 April 2001 (me) Review posted live</div></li><li class="half_rhythm"><div>December 2000 (mec) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1453</span><span class="label">PMID: <a href="/pubmed/20301626" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301626</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/x-ald/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/csnb/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1453&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1453/?report=reader">PubReader</a></li><li><a href="/books/NBK1453/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1453" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1453" style="display:none" title="Cite this Page"><div class="bk_tt">Smith CIE, Berglöf A. X-Linked Agammaglobulinemia. 2001 Apr 5 [Updated 2016 Aug 4]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1453/pdf/Bookshelf_NBK1453.pdf">PDF version of this page</a> (439K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#xla.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#xla.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#xla.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#xla.Genetically_Related_Disorders" ref="log$=inpage&amp;link_id=inpage">Genetically Related Disorders</a></li><li><a href="#xla.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#xla.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#xla.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#xla.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#xla.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#xla.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#xla.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=695[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">BTK</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1474408" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1474408" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1474408" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1474408" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301584" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> X-Linked Severe Combined Immunodeficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> X-Linked Severe Combined Immunodeficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Allenspach E, Rawlings DJ, Scharenberg AM. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301668" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hemophilia B</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hemophilia B<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Konkle BA, Huston H, Nakaya Fletcher S. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301578" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hemophilia A</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hemophilia A<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Konkle BA, Huston H, Nakaya Fletcher S. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301604" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">NR0B1-</i>Related Adrenal Hypoplasia Congenita</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">NR0B1-</i>Related Adrenal Hypoplasia Congenita<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Achermann JC, Vilain EJ. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24006547" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ornithine Transcarbamylase Deficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ornithine Transcarbamylase Deficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Lichter-Konecki U, Caldovic L, Morizono H, Simpson K. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301626" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301626" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e0411f1dd21425a25ab4fac">X-Linked Agammaglobulinemia - GeneReviews®</a><div class="ralinkpop offscreen_noflow">X-Linked Agammaglobulinemia - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T20:50:42-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal101&amp;ncbi_phid=CE8808FDE04015210000000006D70270&amp;ncbi_session=CE8808FDE0411F11_1751SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1453%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1453&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1453/&amp;ncbi_pagename=X-Linked Agammaglobulinemia - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8808FDE0411F11_1751SID /projects/books/PBooks@5.22 portal101 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>